• Trifluoperazine 2HCl: Advanced Dopamine D2 Receptor Inhibito

  2026-07-06

  Trifluoperazine 2HCl from APExBIO stands out for its nanomolar potency, exceptional solubility, and proven versatility across neuropharmacology, immunology, and cancer biology research. This article delivers actionable protocol enhancements, troubleshooting insights, and evidence-backed strategies that set a new standard for dopamine D2 receptor inhibitor research.

• Targeting SOCE with YM 58483 (BTP2): A New Era in Fibrosis R

  2026-07-06

  Explore how selective SOCE inhibition by YM 58483 (BTP2) is reshaping translational research in immune modulation and fibrosis, with a deep dive into the mechanistic underpinnings revealed by recent studies on the ORAI2/JNK/NFAT1 axis. This article provides practical guidance for experimental workflows and positions APExBIO’s YM 58483 as a critical tool for next-generation fibrosis and immune assays.

• Optimizing mCherry mRNA Workflows for Robust Fluorescent Pro

  2026-07-05

  EZ Cap™ mCherry mRNA (5mCTP, ψUTP) delivers reliable, immune-evasive red fluorescent protein expression with superior mRNA stability. Learn how this advanced reporter gene mRNA enables high-fidelity cell tracing, troubleshooting, and workflow enhancements for next-generation molecular imaging.

• 1-myristoylglycerophosphocholine in Lipid Signaling and Fibr

  2026-07-04

  1-myristoylglycerophosphocholine (14:0 Lyso-PC) enables researchers to dissect lipid signaling pathways in smooth muscle assays and pulmonary fibrosis models with high specificity. This article translates recent mechanistic breakthroughs into actionable protocols, troubleshooting insights, and advanced applications—anchored by APExBIO’s high-quality reagent.

• CTDNEP1-NEP1R1 Complex: Differential Roles in ER Lipid Homeo

  2026-07-03

  This study elucidates how CTD-nuclear envelope phosphatase 1 (CTDNEP1) differentially depends on its regulatory subunit NEP1R1 to control ER membrane expansion and lipid storage. The findings provide mechanistic insight into the regulation of lipid synthesis and storage, advancing our understanding of organelle homeostasis and protein quality control in mammalian cells.

• FerroOrange Fe²⁺ Fluorescent Probe: Live Cell Iron Detection

  2026-07-03

  FerroOrange empowers precise, live-cell detection of intracellular Fe²⁺, transforming workflows in neurobiology and ferroptosis research. With robust fluorescence enhancement and user-friendly compatibility across key imaging platforms, this APExBIO probe brings reproducibility and specificity to iron metabolism assays where legacy methods falter.

• PTX3 Protects Against Steroid-Induced ONFH via TLR4/NF-κB-FG

  2026-07-02

  This study uncovers a protective mechanism by which pentraxin 3 (PTX3) counters glucocorticoid-induced osteonecrosis of the femoral head (ONFH) through modulation of the TLR4/NF-κB/FGF21 signaling pathway. These findings highlight PTX3 as a potential therapeutic target and offer mechanistic insights for future research into bone preservation strategies under steroid challenge.

• Paroxetine Mesylate: SSRI, CYP2D6 Inhibitor, and Oncology Ut

  2026-07-02

  Paroxetine Mesylate is a selective serotonin reuptake inhibitor (SSRI) with confirmed multi-kinase and cytochrome P450 inhibition. Its characterized in vitro and in vivo activities span neuropsychiatric, oncology, and translational research, supporting robust experimental workflows.

• CTOP (SKU B5135): Reliable μ-Opioid Receptor Antagonist Solu

  2026-07-01

  This article addresses core experimental challenges in opioid receptor research, demonstrating how CTOP (SKU B5135) from APExBIO enables reproducible, data-driven answers for μ-opioid receptor antagonist studies. Integrating scenario-based Q&A and recent literature, it guides researchers towards robust protocol design and interpretation.

• Trichostatin A (TSA) in Organoid Epigenetics: Beyond Oncolog

  2026-07-01

  Explore how Trichostatin A (TSA) revolutionizes epigenetic research in organoid systems and cancer, with a focus on stem cell differentiation and assay optimization. This article reveals new insights for researchers seeking advanced applications of TSA.

• SCH772984 HCl: Advanced Insights into ERK1/2 Inhibition and

  2026-06-30

  Discover how SCH772984 HCl, a potent ERK1/2 inhibitor, reveals novel connections between MAPK pathway inhibition and transcriptional regulation, with direct implications for cancer and metabolic research. This in-depth analysis uniquely integrates mechanistic, assay, and translational perspectives.

• CTOP in Advanced μ-Opioid Receptor Signaling Inhibition Rese

  2026-06-30

  Explore how CTOP, a potent μ-opioid receptor antagonist, enables unprecedented precision in dissecting opioid signaling pathways. This article reveals unique mechanistic insights and practical assay guidance not covered elsewhere.

• Chloramphenicol in Plasmid Surveillance: Modern Assay Design

  2026-06-29

  Explore chloramphenicol's multifaceted role as an antimicrobial agent and bacterial protein synthesis inhibitor in advanced plasmid surveillance assays. This article uniquely connects molecular protocols with real-world resistance transmission, offering guidance for robust research workflows.

• Cholesterol Impairs Lipid Nanoparticle Trafficking in Cells

  2026-06-29

  This study reveals that elevated cholesterol within lipid nanoparticles (LNPs) hinders their intracellular trafficking, leading to impaired nucleic acid delivery. By dissecting the lipid composition using advanced imaging and a DNA tracking platform, the authors clarify how cholesterol disrupts endosomal escape—a critical step for LNP-based gene delivery.

• 3-Bromopyruvate and Cetuximab Synergy Triggers Ferroptosis i

  2026-06-28

  This study demonstrates that co-treatment with 3-bromopyruvate (3-BP) and cetuximab overcomes resistance in colorectal cancer (CRC) cells by inducing autophagy-dependent ferroptosis and apoptosis. Mechanistic insights reveal that restoration of FOXO3a signaling underpins this effect, suggesting actionable targets for overcoming drug resistance in KRAS/BRAF-mutant and acquired-resistant CRC models.

16352 records 1/1091 page Next 12345 下5页 Last page